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Abstract 
AUTOCRINE EFFECTS OF CATECHOLAMINES ON MACROPHAGE RELEASE 
OF INTERLEUKIN-6 
Shaunta D. Poe, B.A in Biology 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University. 
Virginia Commonwealth University, 2006 
Major Director: Jennifer K. Stewart, Ph.D., Associate Professor, Department of Biology 
Effects of norepinephrine (NE) on macrophage cytokine release are complex because 
the cells have both a2 and P2 adrenergic receptors, which mediate opposing actions. 
Furthermore, P2 -adrenergic agonists are reported to have both stimulatory and inhibitory 
effects on interleukin-6 (IL-6). This study was designed to clarify the autocrine role of 
macrophage-derived NE on IL-6 production in activated peritoneal macrophages. Effects 
of NE on IL-6 production in the RAW264.7 macrophage cell-line also were investigated. 
Treatment of activated peritoneal macrophages with endotoxin, the a2-adrenergic 
. . . 
Vl l l  
antagonists yohimbine or RS79948 revealed that the a2-adrenergic receptor mediates a 
stimulatory autocrine action of catecholamines on IL-6 production. When peritoneal 
macrophages were treated with the P 2  antagonist ICI-118,55 1 (ICI), there was both 
inhibition and stimulation of IL-6. Treatment of RAW264.7 macrophages with high and 
low concentrations of NE and various concentrations of ICI provided evidence that the 
concentration of NE determines whether the P2-adrenergic receptor mediates stimulation 
or inhibition of IL-6 production. 
Introduction 
Macrophages are antigen-presenting cells and specialized phagocytes that are 
dispersed throughout the tissues of the body. They play an important role in host defense 
against infection (1 1). When an immune response is elicited, macrophages become 
activated by interferon gamma or bacterial lipopolysaccharide (LPS); this stimulates 
macrophage release of cytokines, which are signaling proteins. Macrophage cytokines 
include interleukins and tumor necrosis factor alpha (IL-1, IL-6, IL-8, IL-10, IL-12 and 
TNFa) (30). These cytokines mediate and regulate many immune responses. Actions of 
TNFa, IL- 1 P, and IL- 12 are pro-inflammatory, whereas IL- 10 has anti-inflanmatory 
actions, and IL-6 functions are mixed. Furthermore, one cytokine can affect production 
and release of another cytokine. For example: the anti-inflammatory cytokine IL- 10 
inhibits the release of IL- 1 P, and IL-12. IL- 1 P and TNFa, each facilitate production of 
the other and stimulate production of IL-6, which then has suppressive effects on TNFa 
expression(l6; 28). Studies with IL-6 knockout mice indicate that IL-6 also inhibits 
macrophage production of IL- 10 and promotes IL- 12 production (2; 2 1). These cytokine 
interactions are illustrated in Figure 1. 
indicates stimulation 
Figure 1 : Interactions of macrophage cytokines. 
Interleukin 6 (ZL-6) 
IL-6 is a 26-kD pleiotropic cytokine secreted by lymphoid and nonlymphoid cells. IL- 
6 functions in haematopoiesis; specifically in the regulation of T cell and B cell growth 
and differentiation (10; 17). It is released as a pro-inflammatory cytokine in response to 
infection, trauma, neoplasia and other cytokines such as interleukin-1 (IL-1 P) and tumor 
necrosis factor a (TNF- a)  (28). IL-6 also is known to have a key function as a mediator 
in inflammation during the acute-phase response (10; 15; 20; 27). 
Catecholam ines in Macrophages 
More than twenty years ago Balter and Schwartz showed that macrophages take up 
the catecholamine norepinephrine (NE) (3). More recently, Scott Brown in our laboratory 
demonstrated that .the RAW 264.7 macrophage cell line synthesizes norepinephrine and 
dopaniine (4). Several studies now suggest that both mouse and human macrophages 
release NE (4; 18; 24). Furthermore, our laboratory and others have demonstrated that 
macrophage-derived norepinephrine has autocrine effects on macrophage release of 
cytokines (6; 9; 23; 24). 
Actions of Epinephrine and Norepinephrine on Macrophages 
Specific effects of the catecholamines epinephrine and norepinephrine are determined 
by adrenergic receptor activation. Macrophages express two adrenergic receptors, a2 and 
p2, which mediate different effects on synthesis and release of cytokines (1; 7; 8; 13). 
Previous studies indicate that the binding of NE to the P2 adrenergic receptor inhibits the 
production of TNFa, IL- 12, IL-1 P and stimulates IL-10 production, whereas binding to 
the a2 receptor has opposite effects on the production of these cytokines (6; 8; 13; 13). 
Adrenergic effects on IL-6 are unclear. P2-adrenergic agonists are reported to have 
both stimulatory and inhibitory effects on IL-6 (20; 26; 3 I), and .these effects are 
hypothesized to be dependent on the concentration of agonist and the concentration of 
TNFa that is present (20; 28). For example, in the absence of TNFa, norepinephrine 
binding to ,the P2 adrenergic receptor stimulates increased production of cyclic AMP 
(CAMP), which directly stimulates IL-6 production in several types of cells (27). 
Nevertheless, this stimulation of IL-6 is small compared to stimulation by TNFa, a pro- 
inflammatory cytokine that stimulates a large increase in IL-6 production. P2-adrenergic 
agonists inhibit TNFa production and, therefore, inhibit TNF-stimulated IL-6. The chart 
below clarifies the current hypothesis of IL-6 regulation in the absence of signals that 
trigger pro-inflammatory cytokines, such as TNFa, and in the presence of pro- 
inflammatory stimuli, such as the bacterial endotoxin, lipopolysaccharide (LPS). 
No Inflammatory Signals: 
Vehicle undetectable 11-6 
t t NE -b CAMP-b IL-6 (compared to vehicle) 
Pro-Inflammatory Signals: 
LPS+NE. tcAMP A b N F  1 IL-6 (compared to LPS alone) 
As mentioned above, macrophages have both a2 and P2 adrenergic receptors, which 
mediate opposite effects on CAMP and opposite effects on TNFa (23). Based on the chart 
above, one would expect opposite effects of these adrenergic receptors on IL-6. If NE 
exerted equal but opposite effects on a2 and p 2  receptors, any overall effect would be 
canceled out; however, low concentrations of NE (< 100 nM) usually stimulate only 
a2-adrenergic receptors (13; 23), and at higher NE concentrations, effects on 
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P2-adrenergic receptors are usually dominant. These concentration-dependent effects may 
be particularly complex in recruited peritoneal macrophages that release NE and are 
exposed in vivo to NE from other sources. Exposure of these cells to high concentrations 
of NE or epinenephrine in the animal prior to harvest of macrophages would be expected 
to down-regulate P2-adrenergic receptors(l4). The goal of this study was to investigate 
effects of adrenergic stimulation on IL-6 production in activated peritoneal macrophages 
and the RAW264.7 niacrophage cell-line. 
Methods and Materials 
Primary Macrophage Recruitment 
Female CBAIJ mice, age 6-8 weeks, were obtained from Harlan (Indianapolis, IN) and 
housed in the animal facility of Virginia Commonwealth University under the guidelines 
of the University Institutional Animal Care and Use Committee (IACUC). All Animal 
protocols were approved by the IACUC. 
A single intra-peritoneal injection (0.5 ml) of Complete Freund's Adjuvant (CFA), 
diluted 1 : 1 with Dulbecco's Phosphate-Buffered Saline (Sigma, St. Louis, MO), was used 
for recruitment of macrophages. Fourteen days following injection, the mice were 
euthanized with C02, and peritoneal exudates were harvested and washed twice with 
Hanks' balanced salt solution (Invitrogen, Carlsbad, CA). The cells were resuspended in 
complete RPMI (cRPMI), consisting of RPMI 1640 (Invitrogen) supplemented with 10% 
heat inactivated fetal bovine serum, 1 % L-glutamine, 1 % non-essential amino acids, 1 % 
minimal essential medium vitamins, 100 unitslml penicillin and 100 pg/ml streptomycin, 
and allowed to adhere for 4 hours. Non-adherent cells were discarded, and adherent cells 
were washed with cRPMI and incubated at 37" C in 5% C02. 
RA W 264.7 Macrophage Cell Line 
Murine macrophages from the RAW264.7 cell line (ATTC, Rockville, MD) were 
cultured in cRPMI. Cell cultures were maintained at 37' C in 5% C02 in 75 cni2 tissue 
culture flasks (Costar Brand, Fisher Scientific, Suwanee, GA). The cultures were sub- 
cultured twice weekly. 
Effects of LPS and Adrenergic Antagonists or Agonists on ZL-6 
Primary exudate cells (3.0 x lo6) or RAW264.7 macrophages (0.75 x lo6) were added 
to each well of a 24-well tissue culture plate and incubated for 24 hrs at 37C in 5% COz 
to allow for macrophage adherence. Approximately 50% of the exudate cells were 
adherent, and the cells did not proliferate in culture. The RAWS264.7 cells doubled 
within 24 hours; therefore, the final concentration of all macrophages was (1.5 x lo6) 
cells per well. The cells were washed twice with warm (37'C) phosphate buffered saline 
(PBS), pH 7.4, then incubated for 24 hrs in 500 yl of serum-free RPMI 1640 medium 
with and without LPS (E. coli - serotype 055:B5, Sigma, St. Louis, MO) and adrenergic 
agonists or antagonists, including ICI 1 18,55 1, RS79948 and isoproterenol hydrochloride 
from Tocris, (Ellisville, MO) and yohimbine from Sigma-RBI, (St. Louis, MO) at 
concentrations indicated in the figure legends. Extracellular fluid was removed and 
centrifuged at 500 xg for 10 minutes at 5C to remove cellular debris, and the supernatant 
was frozen at -20C until assayed for IL-6. The remaining macrophage monolayer within 
each well was washed once with RPMI 1640 and twice with PBS. All PBS was removed, 
and the monolayer was lysed for subsequent measurement of total cellular protein. The 
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cell monolayer was lysed with 150 pl of ice cold buffer containing 0.05 M Tris (pH 7.9 ,  
0.3 M NaC1,2 rnM EDTA, 1 .O% Triton-X 100,2 pg/ml leupeptin, 1 pg/ml aprotinin and 
0.2 mM phenylmethylsulfonylfluoride. Protein concentrations of the lysates were 
determined with the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA) and 
read at 590 nnl in the pQuant Universal Microplate reader purchased from Bio-Tek 
Instruments (Winooski, VT). 
Measurement of ZL-6 
Extracellular IL-6 concentrations were assayed with the OptEIA Multi Component 
ELISA Set for Mouse IL-6 from BD Biosciences, (San Diego, CA). The assays were 
performed in accordance with the manufacturer's instructions. The plates were read at 
450 and 570 nm with a pQuant Universal Microplate Spectrophotometer. IL-6 
concentrations were calculated with the manufacturer's KC4 software. 
MTT Viability Assay 
This MTT assay protocol is an adaptation of Mosmann (19), Carmichael et al. ( 9 ,  and 
Pozzolini et al. (22). RAW264.7 macrophages were plated in 96-well tissue culture 
treated plates (Costar) at a density of 2.0 x lo5 cells/well. The cells were treated with 
vehicle (media alone), LPS (30 nglml), ICI 118,551(10 pM), or 10% DMSO (a 
concentration that kills cells) and incubated at 37'C in 5% COz for 24 h. MTT (3-(43- 
dimethylthiazol-2-y1)-2,5-diphenyltetrazolium bromide; Sigma-Aldrich, (St. Louis, MO) 
was added to each well at a final concentration of 0.5 mg/ml and incubated for an 
additional 4 h. After 4 h, all media was aspirated and the cells were lysed with a buffer 
containing sodium dodecyl sulfate (SDS; Sigma-Aldrich, St. Louis, MO) dissolved in 
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50% N, N-dimethyl-formamide (DMF; Sigma-Aldrich, St. Louis, MO) and incubated 
overnight at 37'C. The plate was read at 570 nrn with the pQuant Universal Microplate 
Spectrophotometer. Absorbance was proportional to the number of viable cells. 
Data Analyses 
Analysis of variance (ANOVA) and the Neuman-Keuls test were used to compare 
effects of LPS and LPS plus ICI adrenergic antagonists on macrophage production of IL- 
6. The analyses were performed with Prism software (Graphpad, San Diego, CA). 
Differences were considered statistically significant at P < 0.05. 
Results 
Pz-adrenergic modulation of IL-6 
Recruited peritoneal macrophages stimulated with 10 ng/ml and 30 ng/ml of LPS 
consistently released elevated levels of IL-6 over that observed with vehicle (figure 2). 
We have previously shown that norepinephrine (NE) released by these cells has autocrine 
effects on the production of IL-1 P (9). To test whether LPS-stimulated IL-6 is modulated 
by autocrine actions of NE on the Pz-adrenergic receptor, the following experiment was 
carried out with the P2 antagonist ICI 118,55 l(IC1). Macrophages were stimulated with 
30 ng/ml of LPS, and the pz receptors were blocked with ICI. There was an increase in 
IL-6 production in cells treated with ICI plus LPS over that observed with LPS alone 
(Figure 3). In contrast, there was a significant decrease in IL-6 compared to LPS alone 
when cells were stimulated with 10 ng/ml of LPS plus ICI (Figure 4A). Although these 
findings initially suggested opposite effects of the P2 antagonists at low and high 
concentrations of LPS, repeated studies showed inconsistent modulation of IL-6 release 
that was not dependent on the concentration of LPS (Figure 4B). Subsequently peritoneal 
macrophages were treated with LPS and varying concentrations of ICI. There was a 
significant inhibition of IL-6 production with 0.5 pM and 1.0 pM concentrations of ICI 
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(Figure 5). Although these findings seem to suggest that low and high concentrations of 
ICI exert opposite effects on IL-6 production, repeated studies again revealed inconsistent 
modulation of IL-6 by both low and high concentrations of ICI (Figure 5B). An MTT 
assay of cell viability revealed no effects of ICI on cell numbers that could account for 
these results (data not shown). 
Peritoneal macrophages take up NE from extracellular fluids (3) and exposure to NE 
from various sources in vivo may influence the amount of NE released by these cells. The 
extracellular NE concentration is expected to affect the actions of the P2 antagonist ICI, 
but it was not possible to measure extracellular NE released by only 3 x lo6 macrophages 
in a 24 well culture plate. Because RAW264.7 macrophages do not release significant 
quantities of NE until 48 h after LPS (4), these cells were used to determine the effects of 
exogenous NE and ICI on the release of IL-6 that peaks 24 h after LPS stimulation. 
Figure 6 shows the effects of various concentrations of LPS on the RAW264.7 
macrophage release of IL-6. Similar to the peritoneal macrophages, there was a consistent 
elevation in the production of IL-6 with increasing amounts of LPS. RAW264.7 cells 
were then treated with exogenous NE to determine the effects of NE on the LPS- 
stimulated release of IL-6, and in selected experiments, P2-adrenergic receptors were 
blocked with ICI. When cells were treated with 1 pM NE and LPS, there was a 
significant decrease in IL-6 production compared to LPS alone (Figure 7A) and blocking 
the P2 receptor with ICI increased IL-6 production. This finding suggests that the P2- 
adrenergic receptor mediates inhibitory effects of 1 pM NE on IL-6. When cells were 
treated with 0.01 pM NE and LPS, there was an increase in IL-6 production compared to 
LPS alone (Figure 7B). This finding is consistent with observations that low 
concentrations of NE bind to a2 receptors and stimulate production of TNFa (23). 
However, blocking the P2 receptor in RAW264.7 cells with ICI appeared to reverse this 
effect suggesting that the P2 receptor also mediates stirnulatory effects of low 
concentrations of NE (Figure 7B). 
RAW264.7 cells were then treated with LPS and the non-selective P agonist 
isoproterenol. When the cells were given 1 pM Isoproterenol or 10 pM Isoproterenol 
there was a significant decrease in the release of IL-6 (Figure 8). This finding is 
consistent with the results shown in figure 7A, suggesting that P agonists at 1 pM inhibit 
IL-6 production. 
az- adrenergic modulation of IL-6 
To test the autocrine effects of NE on IL-6 that are mediated by the a2-adrenergic 
receptor, peritoneal macrophages were treated with LPS and the a2-adrenergic antagonist 
yohimbine or RS79948. Both yohimbine and RS79948 cells decreased IL-6 production, 
(Figure 9), which suggest the a2-adrenergic receptor mediates increased production of 
IL-6. 
Discussion 
Effects of NE and epinephrine on macrophage cytokine release are complex because 
the cells have both a2 and P2 adrenergic receptors, and these receptors usually mediate 
opposing actions. The actions of adrenergic receptor modulation of IL-6 are controversial 
and difficult to interpret because P 2  -adrenergic agonists are reported to have either 
stimulatory or inhibitory effects on IL-6, depending on the duration and concentration of 
the agonist, the effects on TNFa, which modulates IL-6 transcription, and interactions 
with the CAMP signal transduction pathway (15; 20). Previous studies also indicate that 
TNFa mediates inhibitory effects of the P-adrenergic receptor on IL-6 production (27). A 
few studies have also suggested that a-adrenergic agonists may influence macrophage IL- 
6 production (25; 27; 28), but no clear pattern of modulation has emerged. This study was 
designed to help clarify the autocrine role of macrophage derived NE on IL-6 production. 
In this study, treatment of peritoneal macrophages with LPS plus a2-adrenergic 
antagonists yohimbine or RS79948 over 24 hour revealed that the a*-adrenergic receptor 
mediates a stimulatory autocrine action of catecholamines on IL-6 production (9). These 
findings are consistent with previous evidence that this receptor mediates stimulatory 
autocrine effects on TNFa and IL-1P (23; 24). However, when peritoneal macrophages 
were treated with the p2 antagonist ICI, there was both inhibition and stimulation of IL-6. 
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Treatment of RAW264.7 niacrophages with high (1 pM) and low concentrations of NE 
and various concentrations of ICI suggested that effects of ICI depend on the 
concentration of NE. Our observations that ICI blocked the inhibitory effects of the 
higher concentration of NE are consistent with P2-adrenergic inhibition of TNFa 
production (25) which should inhibit production of IL-6. It is surprising, however, to find 
that the P2 antagonist ICI blocked stimulatory effects of a low concentration of NE. This 
concentration of NE was expected to bind only to a2 -adrenergic receptors (12). It is 
conceivable (although unlikely) that binding of 0.01 pM NE to the P2-adrenergic receptor 
increased cAMP sufficiently to directly stimulate IL-6 production (28), but not enough to 
decrease TNFa, which would decrease IL-6 production. Alternatively, the macrophage 
P2-adrenergic receptor may mediate effects on other unidentified pathways that regulate 
IL-6 production. 
It is important to recall that release of IL-6 may be directly mediated by TNFa or 
directly by LPS stimulation (27). It is known that TNFa is released early during an 
inflammatory response and reduced in the presence of NE. An increase in intracellular 
cAMP occurs after P-adrenergic receptor stimulation, which decreases the levels of 
TNFa, which then decreases the levels of IL-6. In the absence of TNFa, however, 
binding of NE to P2-adrenergic receptors results in an increase in cAMP and an increase 
in IL-6 (8; 28). 
Other laboratories also have reported opposite effects of different concentrations of P2 
agonists on IL-6. High concentrations of the P 2  agonist terbutaline (1 0" M) significantly 
increase IL-6 production in renal macrophages; whereas lower concentrations (lo-* M) 
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decrease IL-6 production (20; 28). However, these concentration effects are opposite 
those we observed with NE. Treatment of the human macrophage cell line, U-937, with 
the p agonist clenbuterol decreases LPS-stimulated IL-6 after 6 hours (1 5), which is 
consistent with our observation that isoproterenol decreases IL-6 production in 
RAW264.7 macrophages. In other cells, such as rat thymic epithelial cells, in the absence 
of LPS or inflammatory cytokines the P agonist isoproterenol increases IL-6 production 
in a dose dependent manner (3 1). Also, IL-6 production in-vivo is increased by 
isoproterenol(29). 
In summary, the results of this study suggest that catecholamines released by 
peritoneal macrophages have stimulatory autocrine effects on IL-6 production that is 
mediated by a2-adrenergic receptors and both stimulatory and inhibitory autocrine effects 
mediated by Pz-adrenergic receptors. The inhibitory effects are postulated to require 
relatively high concentrations of NE (- 1 pM), based on concentration-response studies 
with RAW264.7 macrophages. 
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Figure 2. Effects of LPS on extracellular IL-6 released by murine peritoneal 
macrophages. Cells were plated and treated with vehicle (medium) or the 
concentrations of LPS shown below the bars. Macrophages were incubated for 24 h after 
treatment, and extracellular IL-6 was measured with an ELISA. * P 5 0.001 compared to 
vehicle by ANOVA and .the Newman-Keuls test. Bars represent mean f SE of 3-4 
replicates. 
Figure 3. Effects of LPS and the pz adrenergic antagonist ICI 118,551 on 
extracellular IL-6 released by murine peritoneal macrophages. Cells were plated and 
treated with vehicle (medium), the concentration of LPS shown below the bar, or LPS + 
10 yM concentration of antagonist ICI 1 18,55 1. Macrophages were incubated for 24 h 
after treatment, and extracellular IL-6 was measured with an ELISA. *P 5 0.05 compared 
to the same concentration of LPS alone by ANOVA the Newman-Keuls test. Bars 
represent mean + SE of 3-5 replicates. 
Figure 4. Effects of the p2 adrenergic antagonist ICI 118,551 (ICI) on LPS- 
stimulated IL-6 released by murine peritoneal macrophages. A and B represent 
duplicate experiments. Cells were plated and treated with vehicle (medium), the 
concentrations of LPS shown below the bar, or LPS + 10 pM ICI 1 18,55 1. Macrophages 
were incubated for 24 h after treatment, and extracellular IL-6 was measured with an 
ELISA. *P 5 0.01 and **P 50.001 compared to the same concentration of LPS alone by 
ANOVA and the Newman-Keuls test. Bars represent mean f SE of 3-4 replicates. 
Figure 5. Effects of the p2 adrenergic antagonist ICI 118,551 (ICI) on the LPS- 
stimulated IL-6 released by murine peritoneal macrophages. A. Cells were plated 
and treated with vehicle (medium), concentrations of LPS shown below the bars or LPS + 
the concentration of the antagonist shown below the bars. Macrophages were incubated 
for 24 h after treatment, and extracellular IL-6 was measured with an ELISA. B. Repeat 
of experiment A with two concentrations of ICI. *P I 0.01 and **P 5 0.001 compared to 
LPS alone by ANOVA and the Newman-Keuls test. Bars represent mean + SE of 4-5 
replicates. 
Figure 6. Effects of LPS on extracellular IL-6 produced by RAW 264.7 cell line. 
Cells were plated and treated with vehicle (medium) or the concentrations of LPS shown 
below the bars. RAW 264.7 cells were incubated for 24 h after treatment, and 
extracellular IL-6 was measured with an ELISA. *P 10.05 and **P 5 0.001 compared to 
vehicle by ANOVA and the Newman-Keuls test. Bars represent mean + SE of 3-4 
replicates. 
Figure 7. Effects of Norepinephrine (NE) and the pz adrenergic antagonist ICI 
118,551 (ICI) on the LPS-stimulated IL-6 released by RAW 264.7 cell line. 
A. NE = 1 BM; B. NE = 0.01 WM. Cells were plated and treated with vehicle (medium), 
luM NE, .O1 uM NE or LPS + NE + the concentrations of ICI 118,551 shown below the 
bars. RAW 264.7 cells were incubated for 24 h after treatment, and extracellular IL-6 
was measured with an ELISA. *P 10.01 compared to LPS alone and +P 5 0.01 
compared to LPS + NE by ANOVA and the Newman-Keuls test. Bars represent mean k 
SE of 4-5 replicates. 
Figure 8. Effects of the P adrenergic agonist Isoproteranol on the LPS stimulated IL- 
6 released by RAW 264.7 cell line. Cells were plated and treated with vehicle (medium), 
LPS or LPS + the concentrations of Isoproteranol shown below the bars. RAW 264.7 
cells were incubated for 24 h after treatment, and extracellular IL-6 was measured with 
an ELISA. *P 5 0.001 compared to LPS alone by ANOVA and the Newman-Keuls test. 
Bars represent mean f SE of 5 replicates. 
Figure 9. Effects of LPS and the a2 adrenergic antagonist yohimbine (YOH) and 
RS79948 (RS) on LPS-stimulated IL-6 released by murine peritoneal macrophages. 
A. Experiments with Yoh; B. Experiments with RS. Cells were plated and treated with 
vehicle (medium), the concentrations of LPS shown below the bar, LPS + 10 pM 
yohimbine or LPS + 1 pM RS79948. Macrophages were incubated for 24 h after 
treatment, and extracellular IL-6 was measured with an ELISA. *P 5 0.01 compared to 
the corresponding concentration of LPS alone by ANOVA and the Newman-Keuls test. 
Bars represent mean f SE of 3-5 replicates. 
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